Connor, Clark & Lunn Investment Management Ltd. Nkarta, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
BUY
$1.31 - $6.6 $40,603 - $204,567
30,995 Added 214.78%
45,426 $299,000
Q3 2023

Nov 13, 2023
SELL
$1.39 - $2.29 $70,478 - $116,112
-50,704 Reduced 77.84%
14,431 $20,000
Q2 2023

Aug 10, 2023
BUY
$2.19 - $5.17 $96,427 - $227,640
44,031 Added 208.64%
65,135 $142,000
Q1 2023

May 09, 2023
BUY
$3.37 - $6.3 $19,441 - $36,344
5,769 Added 37.62%
21,104 $74,000
Q4 2022

Feb 10, 2023
BUY
$5.14 - $14.35 $78,821 - $220,057
15,335 New
15,335 $91,000

Others Institutions Holding NKTX

# of Institutions
126
Shares Held
66.5M
Call Options Held
173K
Put Options Held
20K
View Full List

About Nkarta, Inc.

NKTX Quotes by TradingView
  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $116M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email